Cross-Sector entity
UBS Group is most often covered alongside Weiss Ratings, which appears in 10 of these 20 stories. Across a 58-day span, the pace is roughly 2.4 stories per week. The busiest single day carried 4. Coverage clusters in markets, which accounts for 7 of those 20, with the remainder spread across 10 other categories.
22 verified stories tracked
Last mentioned: 22h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
UBS Group is most often covered alongside Weiss Ratings, which appears in 10 of these 20 stories. Across a 58-day span, the pace is roughly 2.4 stories per week. The busiest single day carried 4. Coverage clusters in markets, which accounts for 7 of those 20, with the remainder spread across 10 other categories. Each carries 2 original sources on average. Negative sentiment appears in 0% of the tracked stories. We currently track 20 Cross-Sector stories that mention UBS Group, published between June 28, 2026 and August 24, 2026.
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering UBS Group. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen issues opposing ratings
Downgraded T1 Energy from Sell to Strong Sell and upgraded SM Energy from Buy to Strong Buy.
Dividend Payment Date
Quarterly dividend paid to shareholders of record July 24.
T1 Energy earnings and BTIG target move
T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.
Truist raises SM Energy target
Increased price target from $37.00 to $43.00 and maintained a Buy rating.
SM Energy quarterly results
SM Energy reported $2.19 earnings per share for the quarter.
Dividend Record Date
Shareholders of record qualify for $0.77 quarterly dividend.
Q2 Earnings Release
Kaiser Aluminum reports EPS $5.53, beats estimates by $2.87; revenue $1.26B surpasses $1.12B estimate.
Two updates on SM Energy
Susquehanna lifted its SM target from $31 to $32 (Neutral); Raymond James lowered its target from $55 to $48 (Outperform).
JPMorgan Cuts Target; Stock Jumps
JPMorgan reduced its PG price target from $164 to $162 with an Overweight rating; P&G declared a $1.0885 dividend and the stock rose 2.3% on cost‑cut news.
UBS initiates SM Energy
Started coverage with a Buy rating and a $36.00 target price.
Bank of America Revises Down
Bank of America lowered its PG price objective from $170 to $166, keeping a Buy rating.
Wells Fargo Reaffirms Underweight
Wells Fargo reiterates underweight rating, sets $158 price target.
UBS Lifts Price Target
UBS raises Kaiser Aluminum target to $179 from $176, maintains neutral rating.
Weiss Ratings reaffirms T1 Energy sell
Reaffirmed a Sell (D-) rating on T1 Energy.
Schikan sells 30,712 shares
Schikan sold an additional 30,712 shares at $35.49, totaling $1,089,969.
BTIG Reiterates Buy with $19 Target
BTIG Research reaffirmed a buy rating and issued a $19.00 price target, representing 107.63% upside.
HC Wainwright reiterates buy rating
HC Wainwright reaffirmed its buy rating on Pharvaris shares.
Bernstein assumes T1 Energy coverage
Set a Market Perform rating and a $9.00 price objective.
Wall Street Zen Downgrades
Wall Street Zen downgraded McGraw Hill from 'buy' to 'hold'.
Multiple Banks Revise Downward
UBS cut target to $14 (neutral); JPMorgan cut to $20 (overweight); Baird cut to $16 (outperform); Weiss upgraded sell rating to (d) from (d-).
Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Source: themarketsdaily.com · dailypolitical.com
Mitsubishi UFJ's Q2 13F shows a 22.3% reduction in Nike and 6.4% in Zoetis, just as sell-side targets on NKE cluster at $42–$47. For finance professionals, the filings highlight institutional rebalancing, ownership concentration, and analyst caution as key sentiment signals.
Source: Ticker Report · Watch List News
Single-family rental REIT American Homes 4 Rent has a modestly reduced $38 price target from Morgan Stanley, still above a $36.78 consensus and leaving 11% upside. The maintained Overweight rating reinforces the resilience of the SFR asset class amid housing supply constraints.
Morgan Stanley trimmed its American Homes 4 Rent target to $38 from $38.50 while keeping an Overweight rating, against a $36.78 consensus and Moderate Buy average. Equity research actions from Jefferies, UBS, RBC, Mizuho, and Compass Point reveal a broadly constructive but price-sensitive stance on the REIT.
Source: themarketsdaily.com · tickerreport.com
Verra Mobility shares plunged 12% on August 8, 2026, despite beating Q2 earnings estimates. Analyst consensus is 'Reduce' with a $7 target, while Vistance Networks also gapped down amid mixed signals including a $5 dividend and institutional buying.
Source: themarketsdaily.com · tickerreport.com
SoFi Technologies shares jumped 3.7% on August 4, 2026, even as multiple analysts slashed price targets, creating a tension between market momentum and cautious research. With a PE of 38.96, beta of 2.17, and consensus Hold rating, the fintech’s next move hinges on whether profitability can catch up with valuation.
Source: tickerreport.com · dailypolitical.com
Halozyme Therapeutics posted a massive Q2 beat and raised FY2026 EPS guidance to $8.65-$9.00, well above the $8.02 consensus, triggering a two-day stock surge past $103. With a forward P/E near 11.5x and a PEG ratio of 0.36, the market is repricing the stock after realizing the royalty growth was underestimated.
Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Source: dailypolitical.com · themarketsdaily.com
CBRE Group's above-consensus EPS guidance underscores the commercial real estate sector's momentum, driven by technology-driven services. For PropTech startups and investors, it signals growing client spending on smart buildings, data analytics, and digital brokerage platforms.
Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Source: tickerreport.com · themarketsdaily.com
Nayax shares jumped 4.7% on Monday after a series of analyst upgrades, despite a Q1 earnings miss. With a market cap of $2.47 billion and a rich P/E of 85, the cashless payment provider for unattended retail faces both secular tailwinds and profitability scrutiny. Consensus price target stands at $78.16, offering 15.9% upside.
TeraWulf Inc. surged 7% on Monday to $19.43 after multiple analyst upgrades, even after a massive Q1 EPS miss. With a $9.45 billion market cap and a sky-high debt-to-equity ratio of 33, the Bitcoin miner’s stock is a pure play on crypto momentum, as consensus targets reach $34.60 and one analyst calls for $40.
Source: tickerreport.com · dailypolitical.com
Kaiser Aluminum's Q2 2026 EPS of $5.53 blasts past estimates by 108%, with revenue reaching $1.26B. Despite the beat, the stock slipped 0.03% to $164.32 amid insider sales and mixed analyst targets. The $0.77 quarterly dividend and strong liquidity ratios offer some reassurance.
Source: MarketBeat · themarketsdaily.com
Monarch Casino & Resort posted a second-quarter earnings beat of $0.11 per share on revenue strength, driving the stock up 1.1% to $124.38. Valuation metrics remain solid with a P/E of 21.08 and a 1% dividend yield, but a recent CEO stock sale and mixed analyst ratings signal a cautious bias. Truist’s $144 price target offers the most bullish outlook, while Stifel sits at $102.
Source: MarketBeat · tickerreport.com
Procter & Gamble shares rose 2.3% on news of 7,000 non‑manufacturing job cuts aimed at boosting margins, alongside a brand‑boosting Head & Shoulders partnership with USA Gymnastics. The move highlights how cost efficiency and brand marketing are driving retail‑sector confidence.
Procter & Gamble gained 2.3% despite multiple analysts lowering price targets, thanks to a solid dividend yield and planned job cuts of up to 7,000. With a moderate buy consensus and an average target of $161.42, value seekers see a 6.6% upside.
Source: MarketBeat · themarketsdaily.com
Morgan Stanley lowered its BlackRock (BLK) price target to $1,383 while maintaining Overweight, implying a 34% gain. The consensus remains Moderate Buy with an average target of $1,270.72. Diverging analyst revisions signal both caution and opportunity for the asset management giant.
Source: Zolmax · Markets Daily
Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
Source: The Lincolnian Online · Bbns
Wall Street analyst BTIG reaffirmed a buy rating and $19 target for McGraw Hill (MH), projecting a 107.63% gain from its depressed $9.15 share price. The call highlights deep value in the educational publisher as the entire edtech sector undergoes a post-pandemic correction. With a consensus 'Moderate Buy' and $18.72 target, the stock's extreme undervaluation could reward contrarian edtech investors.
Source: Ticker Report · Daily Political
